Cipla's Pune Manufacturing Unit Loses Drug Sale Licence Over Multiple Violations

Indian pharmaceutical major Cipla has had the drug sale licence of its Pune facility cancelled by authorities. The action follows an inspection that uncovered several regulatory irregularities at the unit. Violations identified include unauthorised advertising practices, improper storage arrangements, and discrepancies in stock records. Authorities also flagged non-compliance related to product recall procedures. The cancellation reflects growing regulatory scrutiny of pharmaceutical manufacturing standards in India.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.
Discussion (0)
Log in to join the discussion and vote.
Log in